AVMA-endorsed xylazine legislation reintroduced in CongressFebruary 20, 2025The AVMA reintroduced the Combating Illicit Xylazine Act in both the House and Senate. The legislation is reported to provide the U.S. Drug Enforcement Administration (DEA) with tools to help address the illicit drug by scheduling xylazine as a Schedule III drug, ensure common veterinary uses of the drug remain legal, help maintain the availability of the drug on the market for veterinarians, and allow the DEA to track the legitimate supply.
Education Center - SponsoredHow AI-Enabled Diagnostic Platforms are Buying Back Time for Veterinarians and Cliniciansby • Zoetis DiagnosticsIn the right context, AI yields the power to enhance clinical confidence and streamline decision-making – without replacing the human touch that defines the profession.
